Briefly noted: M Sorrell et al. JPGN 2017; 64: 783-88. In this small study with 13 infants (mean gestational age of 28 weeks) who had short bowel syndrome or severe dysmotility and direct bilirubin ≥4 mg/dL (mean 9.8 at enrollment), patients received a fish oil-based lipid emulsion (1 g/kg/d). They were compared with 119 GA-matched controls.
Overall, the authors found the fish oil supplement to be safe. All patients had resolution of cholestasis. They note the difficulty of proving effectiveness and performing studies in this population. “Neonatologists…find themselves faced with …a growing body of uncontrolled data that suggests benefits of an unapproved treatment…An attempt to perform a randomized controlled comparison of a plant-based lipid emulsion to FishLE in preventing PNALD in infants at risk was terminated early after an interim analysis revealed much lower than expected incidence of PNALD…[making] trials ethically problematic.”
My take: The data remain incomplete and make it difficult to use a therapy like Omegaven that is quite expensive (not covered) and not FDA approved. The availability of SMOFlipid is likely to result in less usage of plant-based soy products.
Related blog posts:
- Nutrition Week (Day 2) SMOFlipid
- Neonatal Nutrition Lecture -What We Know Right Now …
- Improving Outlook in Neonatal Nutrition (Part 1)
- Current Mortality from Being Born Premature | gutsandgrowth
- Visual Acuity and LCPUFA | gutsandgrowth
- Weight Gain in Preemies, Neurodevelopmental Outcomes, and Reverse Causation
- New lipid emulsions — lacking data to support usage | gutsandgrowth
- Long-chain polyunsaturated fatty acids, breastmilk… | gutsandgrowth
- Low levels of LCPUFA in Premature Infants Associated with Intravenous Lipids
- Optimizing lipids to minimize cholestasis